Daily Archives: April 17, 2012

Bad Effects of Too Much Sitting? Higher Risk of Death & Unhealthy Life

Is sitting too much dangerous for your health? Yes it is. There are a few health topics on which most doctors and health experts agree — and this is definitely one of them.

Now, a new Australian study led by the University of Sydney has found more evidence that sitting too much increases the risk of dying. This was even after taking into account physical activity, weight and health status of study participants. The study of more than 200,000 Australians is published in the March 26 issue of the Archives of Internal Medicine.

Relying on self-reported data from 22,497 people 45 years or older from the “45 and Up Study” — the largest look at healthy aging in the Southern Hemisphere — the researchers found that compared to people who spent less than four hours a day sitting:

Continue reading

St. Jude Defibrillator Wires Linked to 20-Plus Deaths — Study Says

More than 79,000 people in the United States and 49,000 abroad still have the implants with the faulty wires

Implantable cardioverter defibrillators (ICDs): they’re lifesaving devices. Implanted in the chest to correct risky heart rhythms that can be fatal, they work by triggering electrical shocks to correct irregular heartbeats. Thin wires — known as leads — attach the defibrillator to the heart and are responsible for monitoring irregular beats, then triggering shocks to correct the irregularities when these occur.

But can defibrillators themselves be deadly? Yes, according to a new study by a prominent Minneapolis Heart Institute cardiologist published in a leading cardiology journal.

Continue reading

Vorapaxar Blood Thinner Side Effects: Higher Risk of Internal Bleeding?

In limbo after mixed results, Merck blood clot drug stops heart attack with risk of bleeding

In one of the largest heart-drug studies ever conducted, the new drug Vorapaxar showed an impressive efficacy as a blood thinner — but with an increased risk for internal bleeding as a side effect, researchers said on March 24.

The new type of blood clot preventer being tested by Merck & Co has been hounded by bleeding concerns since January 2011. Then, a safety committee overseeing the 26,449-patient study said the new type of anti-platelet drug bore an increased bleeding risk — making it unsuitable for patients who had suffered a stroke.

Continue reading